Shayakhmetov D. M., Papayannopoulou T., Stamatoyannopoulos G., Lieber, A. (2000) Efficient gene transfer into human CD34+ cells by a retargeted adenovirus vector. Journal of Virology 74:2567-83.
Gaggar, A., Shayakhmetov, D.M., Lieber, A. (2003) CD46 is a cellular receptor for group B adenovirus. Nature Medicine, 9: 1408-12
Li Z, Liu Y, Tuve S, Xun Y, Fan X, Min L, Feng Q, Kiviat N, Kiem HP, Disis ML, Lieber A. (2009) Toward a stem cell gene therapy for breast cancer. Blood, 113(22):5423-33.
Wang H., Liu Y., Li ZY, Liang M, Lieber A. (2009) A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy. Blood, 115(3):592-600
Wang, H., Li ZY., Liu Y., Persson J., Beyer I., Möller T., Koyuncu, D., Drescher M.R., Strauss R., Zhang XB., Wahl JK, Urban N., Drescher C., Hemminki A., Fender P., Lieber A. (2011) Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11, and 14. Nature Medicine, 17(1):96-104.
Beyer I, van Rensburg R, Strauss R, Li Z, Wang H, Persson J, Yumul R, Feng Q, Song H, Bartek J, Fender P, Lieber A. (2011) Epithelial Junction Opener JO-1 Improves Monoclonal Antibody Therapy of Cancer. Cancer Research, 71(22):7080-90.
Richter M., Yumul R., Wang H., Saydaminova K., Ho M., May D., Baldessari A., Gough M., Drescher C., Urban N., Roffler S., Zubieta C., Carter D., Fender P., Lieber A. (2015) Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin, Molecular Therapeutics: Methods and Clinical Development, 2:15005.
Saydaminova K., Ye X., Wang H., Richter M., Chen H., Xu N., Kim J., Papapetrou E., Holmes M., Gregory P., Palmer D., Ng P., Ehrhardt A., Lieber A. (2015) Efficient genome editing in hematopoietic stem cells with helper-dependent Ad5/35 vectors expressing site-specific endonucleases under microRNA regulation. Molecular Therapeutics: Methods and Clinical Development, 1:14057.
Richter M, Saydaminova K, Yumul R, Krishnan R, Liu J, Nagy EE, Singh M, Izsvák Z, Cattaneo R, Uckert W, Palmer D, Ng P, Haworth KG, Kiem HP, Ehrhardt A, Papayannopoulou T, Lieber A. (2106) In vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors. Blood, 128:2206-2217.
Wang H, Georgakopoulou A, Psatha N, Li C, Capsali C, Samal HB, Anagnostopoulos A, Ehrhardt A, Izsvak Z, Papayannopoulou T, et al. In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia. J Clin Invest. 2019;129(2):598-615.
Wang H, Liu Z, Li C, Gil S, Papayannopoulou T, Doering CB, and Lieber A. High-level protein production in erythroid cells derived from in vivo transduced hematopoietic stem cells. Blood Adv. 2019;3(19):2883-94.
Li C, Course MM, McNeish IA, Drescher CW, Valdmanis PN, and Lieber A. Prophylactic in vivo hematopoietic stem cell gene therapy with an immune checkpoint inhibitor reverses tumor growth in syngeneic mouse tumor models. Cancer Res. 2020, 80(3):549-560
Li C, Wang H, Germond A, Ung A, Guerriero K, Ogle J, Nelson V, Jeffrey D, Coles C, Georgakopoulou A, et al. In vivo HSC gene therapy for hemoglobinopathies: a proof of concept evaluation in rhesus macaques. 23rd Annula ASCGT meeting. 2020;abstract #1700